A Mutant Used as a Unique Screening Tool to Identify Cell Wall Synthesis Inhibitors that Reverse -Lactam Resistance in MRSA.

is a leading cause of bacterial infections world-wide. Staphylococcal infections are preferentially treated with -lactam antibiotics, however, methicillin-resistant (MRSA) strains have acquired resistance to this superior class of antibiotics. We have developed a growth-based, high-throughput screening approach that directly identifies cell wall synthesis inhibitors capable of reversing -lactam resistance in MRSA.